

Global Therapeutic Vaccines Market By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , By Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report | 2024-08-01 | 300 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$2655.00
- Business User License \$4425.00
- Enterprise License \$7412.00

Report description:

Therapeutic Vaccines Market Expected to Garner \$135.7 Billion by 2033, Growing at a CAGR of 19.1%

Abstract: The global therapeutic vaccines market is expected to grow primarily due to the growing prevalence of chronic diseases & infectious ailments and technological advancements in vaccine development. The Asia-Pacific region is predicted to witness profitable growth by 2033.

□

As per the report published by Research Dive, the global therapeutic vaccines market was valued at \$26.7 billion in 2023 and is expected to register a revenue of \$135.7 billion by 2033 at a CAGR of 19.1% during the forecast period 2024-2033.

Dynamics of the Market

The increasing incidence of diseases such as cancer, HIV, and neurological and autoimmune diseases, and the growing demand for personalized medicine & targeted therapies are expected to make the therapeutic vaccines market a highly profitable one in the forecast period. Besides, the increased funding and initiatives from governments & NGOs and the expanding applications of therapeutic vaccines beyond infectious diseases are other factors predicted to boost the market growth.

However, according to market analysts, high production costs, complex manufacturing processes, and stringent approval requirements might restrain the growth of the market.

Technological advancements, integration of machine learning & artificial intelligence in vaccine design & development, and growing investments in R&D are predicted to offer numerous growth opportunities for the therapeutics vaccines market in the forecast period. Moreover, continued investments by major market players accelerate vaccine development and availability.

Key Players of the Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The major players of the therapeutic vaccines market include Agenesis Inc., Celldex Therapeutic Inc., Argos Therapeutic Inc., Dendreon Pharmaceuticals LLC, Merck & Co. Inc., GSK plc, Novartis AG, Phio Pharmaceuticals Corp., Pfizer, Inc., AstraZeneca, INOVIO Pharmaceuticals, and BioNTech SE.[]

What the Report Covers[]

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter's five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).[]

[]

[]

Additional benefits you will get with this purchase are:

- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Technology Trend Analysis
- Market share analysis of players by products/segments
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Criss-cross segment analysis- market size and forecast
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Market share analysis of players at global/region/country level
- SWOT Analysis

Key Market Segments

By Product

- Autoimmune Disease Vaccines
- Neurological Disease Vaccines
- Cancer Vaccines
- Infectious Disease Vaccines
- Others

By Technology

- Allogeneic Vaccine

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Autologous Vaccine
- By Region
 - North America
 - U.S.
 - Canada
 - Mexico
 - Europe
 - France
 - Germany
 - Italy
 - Spain
 - UK
 - Rest of Europe
 - Asia-Pacific
 - China
 - Japan
 - India
 - South Korea
 - Australia
 - Rest of Asia-Pacific
 - LAMEA
 - Brazil
 - South Africa
 - Saudi Arabia
 - UAE
 - Rest of LAMEA
- Key Market Players
 - Agenus Inc.
 - Argos Therapeutics, Inc.
 - Celldex Therapeutics Inc.
 - Dendreon Pharmaceuticals LLC
 - GSK plc.
 - Merck & Co. Inc.
 - Novartis AG
 - Pfizer, Inc.
 - AstraZeneca
 - BioNTech SE

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

CHAPTER 4: THERAPEUTIC VACCINES MARKET, BY PRODUCT

4.1. Market Overview

4.1.1 Market Size and Forecast, By Product

4.2. Autoimmune Disease Vaccines

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Neurological Disease Vaccines

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. Cancer Vaccines

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

4.5. Infectious Disease Vaccines

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.5.2. Market Size and Forecast, By Region

4.5.3. Market Share Analysis, By Country

4.6. Others

4.6.1. Key Market Trends, Growth Factors and Opportunities

4.6.2. Market Size and Forecast, By Region

4.6.3. Market Share Analysis, By Country

CHAPTER 5: THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY

5.1. Market Overview

5.1.1 Market Size and Forecast, By Technology

5.2. Allogeneic Vaccine

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3. Autologous Vaccine
 - 5.3.1. Key Market Trends, Growth Factors and Opportunities
 - 5.3.2. Market Size and Forecast, By Region
 - 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: THERAPEUTIC VACCINES MARKET, BY REGION
 - 6.1. Market Overview
 - 6.1.1 Market Size and Forecast, By Region
 - 6.2. North America
 - 6.2.1. Key Market Trends and Opportunities
 - 6.2.2. Market Size and Forecast, By Product
 - 6.2.3. Market Size and Forecast, By Technology
 - 6.2.4. Market Size and Forecast, By Country
 - 6.2.5. U.S. Therapeutic Vaccines Market
 - 6.2.5.1. Market Size and Forecast, By Product
 - 6.2.5.2. Market Size and Forecast, By Technology
 - 6.2.6. Canada Therapeutic Vaccines Market
 - 6.2.6.1. Market Size and Forecast, By Product
 - 6.2.6.2. Market Size and Forecast, By Technology
 - 6.2.7. Mexico Therapeutic Vaccines Market
 - 6.2.7.1. Market Size and Forecast, By Product
 - 6.2.7.2. Market Size and Forecast, By Technology
 - 6.3. Europe
 - 6.3.1. Key Market Trends and Opportunities
 - 6.3.2. Market Size and Forecast, By Product
 - 6.3.3. Market Size and Forecast, By Technology
 - 6.3.4. Market Size and Forecast, By Country
 - 6.3.5. France Therapeutic Vaccines Market
 - 6.3.5.1. Market Size and Forecast, By Product
 - 6.3.5.2. Market Size and Forecast, By Technology
 - 6.3.6. Germany Therapeutic Vaccines Market
 - 6.3.6.1. Market Size and Forecast, By Product
 - 6.3.6.2. Market Size and Forecast, By Technology
 - 6.3.7. Italy Therapeutic Vaccines Market
 - 6.3.7.1. Market Size and Forecast, By Product
 - 6.3.7.2. Market Size and Forecast, By Technology
 - 6.3.8. Spain Therapeutic Vaccines Market
 - 6.3.8.1. Market Size and Forecast, By Product
 - 6.3.8.2. Market Size and Forecast, By Technology
 - 6.3.9. UK Therapeutic Vaccines Market
 - 6.3.9.1. Market Size and Forecast, By Product
 - 6.3.9.2. Market Size and Forecast, By Technology
 - 6.3.10. Rest Of Europe Therapeutic Vaccines Market
 - 6.3.10.1. Market Size and Forecast, By Product
 - 6.3.10.2. Market Size and Forecast, By Technology
 - 6.4. Asia-Pacific
 - 6.4.1. Key Market Trends and Opportunities
 - 6.4.2. Market Size and Forecast, By Product

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.4.3. Market Size and Forecast, By Technology
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. China Therapeutic Vaccines Market
 - 6.4.5.1. Market Size and Forecast, By Product
 - 6.4.5.2. Market Size and Forecast, By Technology
- 6.4.6. Japan Therapeutic Vaccines Market
 - 6.4.6.1. Market Size and Forecast, By Product
 - 6.4.6.2. Market Size and Forecast, By Technology
- 6.4.7. India Therapeutic Vaccines Market
 - 6.4.7.1. Market Size and Forecast, By Product
 - 6.4.7.2. Market Size and Forecast, By Technology
- 6.4.8. South Korea Therapeutic Vaccines Market
 - 6.4.8.1. Market Size and Forecast, By Product
 - 6.4.8.2. Market Size and Forecast, By Technology
- 6.4.9. Australia Therapeutic Vaccines Market
 - 6.4.9.1. Market Size and Forecast, By Product
 - 6.4.9.2. Market Size and Forecast, By Technology
- 6.4.10. Rest of Asia-Pacific Therapeutic Vaccines Market
 - 6.4.10.1. Market Size and Forecast, By Product
 - 6.4.10.2. Market Size and Forecast, By Technology
- 6.5. LAMEA
 - 6.5.1. Key Market Trends and Opportunities
 - 6.5.2. Market Size and Forecast, By Product
 - 6.5.3. Market Size and Forecast, By Technology
 - 6.5.4. Market Size and Forecast, By Country
 - 6.5.5. Brazil Therapeutic Vaccines Market
 - 6.5.5.1. Market Size and Forecast, By Product
 - 6.5.5.2. Market Size and Forecast, By Technology
 - 6.5.6. South Africa Therapeutic Vaccines Market
 - 6.5.6.1. Market Size and Forecast, By Product
 - 6.5.6.2. Market Size and Forecast, By Technology
 - 6.5.7. Saudi Arabia Therapeutic Vaccines Market
 - 6.5.7.1. Market Size and Forecast, By Product
 - 6.5.7.2. Market Size and Forecast, By Technology
 - 6.5.8. UAE Therapeutic Vaccines Market
 - 6.5.8.1. Market Size and Forecast, By Product
 - 6.5.8.2. Market Size and Forecast, By Technology
 - 6.5.9. Rest of LAMEA Therapeutic Vaccines Market
 - 6.5.9.1. Market Size and Forecast, By Product
 - 6.5.9.2. Market Size and Forecast, By Technology

CHAPTER 7: COMPETITIVE LANDSCAPE

- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping Of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

CHAPTER 8: COMPANY PROFILES

8.1. Agenus Inc.

8.1.1. Company Overview

8.1.2. Key Executives

8.1.3. Company Snapshot

8.1.4. Operating Business Segments

8.1.5. Product Portfolio

8.1.6. Business Performance

8.1.7. Key Strategic Moves and Developments

8.2. Argos Therapeutics, Inc.

8.2.1. Company Overview

8.2.2. Key Executives

8.2.3. Company Snapshot

8.2.4. Operating Business Segments

8.2.5. Product Portfolio

8.2.6. Business Performance

8.2.7. Key Strategic Moves and Developments

8.3. Celldex Therapeutics Inc.

8.3.1. Company Overview

8.3.2. Key Executives

8.3.3. Company Snapshot

8.3.4. Operating Business Segments

8.3.5. Product Portfolio

8.3.6. Business Performance

8.3.7. Key Strategic Moves and Developments

8.4. Dendreon Pharmaceuticals LLC

8.4.1. Company Overview

8.4.2. Key Executives

8.4.3. Company Snapshot

8.4.4. Operating Business Segments

8.4.5. Product Portfolio

8.4.6. Business Performance

8.4.7. Key Strategic Moves and Developments

8.5. GSK Plc.

8.5.1. Company Overview

8.5.2. Key Executives

8.5.3. Company Snapshot

8.5.4. Operating Business Segments

8.5.5. Product Portfolio

8.5.6. Business Performance

8.5.7. Key Strategic Moves and Developments

8.6. Merck And Co. Inc.

8.6.1. Company Overview

8.6.2. Key Executives

8.6.3. Company Snapshot

8.6.4. Operating Business Segments

8.6.5. Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Novartis AG
 - 8.7.1. Company Overview
 - 8.7.2. Key Executives
 - 8.7.3. Company Snapshot
 - 8.7.4. Operating Business Segments
 - 8.7.5. Product Portfolio
 - 8.7.6. Business Performance
 - 8.7.7. Key Strategic Moves and Developments
- 8.8. Pfizer, Inc.
 - 8.8.1. Company Overview
 - 8.8.2. Key Executives
 - 8.8.3. Company Snapshot
 - 8.8.4. Operating Business Segments
 - 8.8.5. Product Portfolio
 - 8.8.6. Business Performance
 - 8.8.7. Key Strategic Moves and Developments
- 8.9. AstraZeneca
 - 8.9.1. Company Overview
 - 8.9.2. Key Executives
 - 8.9.3. Company Snapshot
 - 8.9.4. Operating Business Segments
 - 8.9.5. Product Portfolio
 - 8.9.6. Business Performance
 - 8.9.7. Key Strategic Moves and Developments
- 8.10. BioNTech SE
 - 8.10.1. Company Overview
 - 8.10.2. Key Executives
 - 8.10.3. Company Snapshot
 - 8.10.4. Operating Business Segments
 - 8.10.5. Product Portfolio
 - 8.10.6. Business Performance
 - 8.10.7. Key Strategic Moves and Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Therapeutic Vaccines Market By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , By Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report | 2024-08-01 | 300 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$2655.00
	Business User License	\$4425.00
	Enterprise License	\$7412.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-10

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com